Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2009

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known as graft-versus-host disease (GVHD). GVHD is a complication in which the cells of the transplanted bone marrow react against organs and tissues.
Epistemonikos ID: 492335ba6b0d3b7a402f1eb5a0e31dfbc535996f
First added on: May 05, 2024